Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients

Currently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) has been reported in almost all countries globally, and no effective therapy has been documented for COVID-19 and the role of convalescent plasma therapy is unknown. In current study, 6 COVID-19 subje...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases
Main Authors Zeng, Qing-Lei, Yu, Zu-Jiang, Gou, Jian-Jun, Li, Guang-Ming, Ma, Shu-Huan, Zhang, Guo-Fan, Xu, Jiang-Hai, Lin, Wan-Bao, Cui, Guang-Lin, Zhang, Min-Min, Li, Cheng, Wang, Ze-Shuai, Zhang, Zhi-Hao, Liu, Zhang-Suo
Format Journal Article
LanguageEnglish
Published US Oxford University Press 29.04.2020
Subjects
Brief Report
Online AccessGet full text

Cover

More Information
Summary:Currently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) has been reported in almost all countries globally, and no effective therapy has been documented for COVID-19 and the role of convalescent plasma therapy is unknown. In current study, 6 COVID-19 subjects with respiratory failure received convalescent plasma at a median of 21.5 days after first detection of viral shedding, all tested negative for SARS-CoV-2 RNA by 3 days after infusion, and 5 died eventually. In conclusion, convalescent plasma treatment can discontinue SARS-CoV-2 shedding but cannot reduce mortality in critically end-stage COVID-19 patients, and treatment should be initiated earlier.
Bibliography:These authors contributed equally to this article.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiaa228